Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer.
Decker T, Söling U, Hahn A, Maintz C, Kurbacher CM, Vehling-Kaiser U, Sent D, Klare P, Hagen V, Chiabudini M, Falkenstein J, Indorf M, Runkel E, Potthoff K. Decker T, et al. Among authors: potthoff k. BMC Cancer. 2020 Apr 6;20(1):286. doi: 10.1186/s12885-020-06747-y. BMC Cancer. 2020. PMID: 32252684 Free PMC article. Clinical Trial.
Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT.
Jensen AD, Krauss J, Potthoff K, Desta A, Habl G, Mavtratzas A, Windemuth-Kiesselbach C, Debus J, Münter MW. Jensen AD, et al. Among authors: potthoff k. BMC Cancer. 2011 May 19;11:182. doi: 10.1186/1471-2407-11-182. BMC Cancer. 2011. PMID: 21595970 Free PMC article. Clinical Trial.
Randomized controlled trial to evaluate the effects of progressive resistance training compared to progressive muscle relaxation in breast cancer patients undergoing adjuvant radiotherapy: the BEST study.
Potthoff K, Schmidt ME, Wiskemann J, Hof H, Klassen O, Habermann N, Beckhove P, Debus J, Ulrich CM, Steindorf K. Potthoff K, et al. BMC Cancer. 2013 Mar 28;13:162. doi: 10.1186/1471-2407-13-162. BMC Cancer. 2013. PMID: 23537231 Free PMC article. Clinical Trial.
Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multicenter phase IV trial.
Habl G, Potthoff K, Haefner MF, Abdollahi A, Hassel JC, Boller E, Indorf M, Debus J. Habl G, et al. Among authors: potthoff k. BMC Cancer. 2013 Jul 15;13:345. doi: 10.1186/1471-2407-13-345. BMC Cancer. 2013. PMID: 23855804 Free PMC article. Clinical Trial.
Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial.
Potthoff K, Habl G, Bruckner T, Suppan C, Hassel J, Jäger D, Indorf M, Debus J. Potthoff K, et al. BMC Cancer. 2014 Apr 17;14:270. doi: 10.1186/1471-2407-14-270. BMC Cancer. 2014. PMID: 24742019 Free PMC article. Clinical Trial.
Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel.
Marschner N, Salat C, Söling U, Hansen R, Grebhardt S, Harde J, Nusch A, Potthoff K. Marschner N, et al. Among authors: potthoff k. Clin Breast Cancer. 2018 Dec;18(6):e1323-e1337. doi: 10.1016/j.clbc.2018.07.010. Epub 2018 Aug 10. Clin Breast Cancer. 2018. PMID: 30100104 Free article.
Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR.
Fietz T, Lück A, Schulz H, Harde J, Losem C, Grebhardt S, Wolff T, Potthoff K, Müller U, Zaiss M, Kurbacher CM. Fietz T, et al. Among authors: potthoff k. Curr Med Res Opin. 2019 Jul;35(7):1127-1138. doi: 10.1080/03007995.2018.1560200. Epub 2019 Jan 21. Curr Med Res Opin. 2019. PMID: 30557099
VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.
Decker T, Marschner N, Muendlein A, Welt A, Hagen V, Rauh J, Schröder H, Jaehnig P, Potthoff K, Lerchenmüller C. Decker T, et al. Among authors: potthoff k. Breast Cancer Res Treat. 2019 Aug;176(3):637-647. doi: 10.1007/s10549-019-05280-2. Epub 2019 May 21. Breast Cancer Res Treat. 2019. PMID: 31115844 Clinical Trial.
57 results